Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 5/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279898 | 1.00 | MAOB (0.50) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL10138700 | 0.86 | MAOA (0.46) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL29634429 | 0.85 | MAOB (0.52) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL23779534 | 0.85 | MAOB (0.52) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL13745303 | 0.84 | MAOA (0.47) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL6401924 | 0.83 | ALDH1A1 (0.53) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL2464599 | 0.83 | CA1 (0.59) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL30010246 | 0.83 | ALDH1A1 (0.53) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL2650432 | 0.81 | MAOA (0.44) | MAOBMAOACYP19A1CA1CA2 | |
| SCHEMBL2991205 | 0.81 | CA1 (0.46) | MAOBMAOACYP19A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| EP-3207037-B1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3207037-B1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-9902716-B2 | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9902716-B2 | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9902716-B2 | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-27 | — | — | US | disclosed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| CN-1316991-A | Azetidine derivatives, preparation and medicines containing them | AVENTIS PHARMA SA (FR) | 2001-10-10 | — | — | CN | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | MAOB 194/4885MAOA 242/4885CYP19A1 617/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | MAOB 4101/4885MAOA 4268/4885CYP19A1 3446/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | MAOB 122/4885MAOA 172/4885CYP19A1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.